Shares of SciSparc (SPRC) are down 12% after its partner, Clearmind Medicine (CMND) announced a new patent filing in Hong Kong for a non-hallucinogenic treatment targeting major depressive disorder.
Clearmind's patent covers a combination therapy that pairs its proprietary compound MEAI with palmitoylethanolamide (PEA)- an anti-inflammatory molecule supplied through NeuroThera Labs, a wholly owned subsidiary of SciSparc.
The company says the MEAI-PEA formulation is designed to offer a safer alternative to traditional antidepressants without hallucinogenic effects.
Major depressive disorder affects more than 332 million people worldwide, and demand for new treatment options continues to grow. Clearmind noted that the global antidepressant market could exceed $25 billion in 2030, underscoring the commercial potential of the new therapy.
The company recently implemented a 1-for-9 reverse stock split on March 4, 2026.
SPRC is currently trading at $4.14, down 12.47%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.